DESTINY-Breast03 Phase 3 Study Results
Change From Baseline in CA-125 Levels
Among 17 evaluable patients with OVC, a 8 CA-125 responses were observed
80-
Best change from baseline in CA-125, %
60-
40-
20
20
0
SD
PD
SD
ΝΑ
PR
-20-
-40-
28
-60-
-80-
-100
Data cutoff: February 25, 2022.
b b b b b b
b b
PR
SD---
Non-CR/
Non-PD SD SD
SD
PR
SD Non-CR/
Non-PD PR
SD
PR
Starting dose level
1.6 mg/kg
13.2 mg/kg
14.8 mg/kg
16.4 mg/kg
8.0 mg/kg 9.6 mg/kg
CA-125, cancer antigen 125; CR, complete response; GCIG, Gynecologic Cancer InterGroup; NA, not available; OVC, ovarian cancer; PD, progressive disease; PR, partial response; SD, stable disease.
a Patients with baseline CA-125 value and ≥1 postbaseline CA-125 value were included.
b According to the GCIG criteria, patients can be evaluated for response only if they have a baseline sample that is ≥2 × the upper limit of normal obtained within 2 weeks prior to starting treatment. CA-125 response is defined as a ≥50%
reduction in CA-125 levels from a pretreatment sample. The response must be confirmed and maintained for ≥28 days.
ASCO 2022 #3002 Oral
Daiichi-Sankyo
105View entire presentation